Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Subtype terms (3)
More specific conditions that are subtypes of Leukemia, Myelogenous, Chronic, BCR-ABL Positive in the MeSH hierarchy.
- Blast Crisis
10 drugs (7 approved, 3 experimental)
- Leukemia, Myeloid, Accelerated Phase
16 drugs (13 approved, 3 experimental)
- Leukemia, Myeloid, Chronic-Phase
172 drugs (110 approved, 62 experimental)
Drugs by status
Approved for this indication (11)
Phase 4 trials (1)
Phase 3 trials (47)
- azacitidine
- methylprednisolone
- tioguanine
- mercaptopurine
- abl-001
- urea
- blinatumomab
- busulfan
- indigo
- prednisone
- doxorubicin
- tacrolimus
- naltrexone
- bone marrow derived mesenchymal stem cells
- haploidentical mononuclear cells
- Filgrastim
- leucovorin
- allogeneic stem cells
- vincristine
- muromonab cd3
- panobinostat
- pegaspargase
- pentostatin
- pegylated-interferon
- radotinib
- allogeneic hematopoietic stem cells
- sirolimus
- cyclosporine
- mycophenolate
- cyclophosphamide
- +17 more
Phase 2 trials (115)
- fluorothymidine
- allopurinol
- cladribine
- decitabine
- vitamin d3
- cmv-specific t-cells
- dexrazoxane
- axitinib
- allogeneic natural killer cells
- allogeneic tumor cell vaccine
- plerixafor
- maraviroc
- at9283
- sorafenib
- venetoclax
- bendamustine
- bkt-140
- pri-724
- clofarabine
- dc vaccine
- valproic acid
- succimer
- eltrombopag
- entinostat
- parathyroid hormone
- gemtuzumab ozogamicin
- oblimersen sodium
- aciclovir
- leuprolide
- trametinib
- +85 more
Phase 1 trials (79)
- 19-28z t cells
- afatinib
- ahn-12
- olaparib
- bafetinib
- belinostat
- bp1001
- lenalidomide
- temsirolimus
- cyt107
- enzalutamide
- fluorouracil
- hsp70
- icaspase9-transduced t cells
- idelalisib
- il-7
- ilorasertib
- nivolumab
- ioversol
- hyaluronidase (human recombinant)
- itacitinib
- kw2449
- lenvatinib
- tozasertib
- opb-51602
- palbociclib
- ciclopirox
- pexidartinib
- bms-936559
- ipilimumab
- +49 more
Organizations
Organization Involved with Phase 4 Indications (40)
- Pfizer
- Dong-A Pharmaceutical
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- PETHEMA Foundation
- Ajou University
- Azienda Ospedaliera San Gerardo di Monza
- Gachon University
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Hainan People's Hospital
- Inje University
- Korea University
- McGill University
- Onze Lieve Vrouw Hospital
- Postgraduate Institute of Medical Education and Research
- Seoul National University
- Universidad Autonoma de Nuevo Leon
- University of Milan
- Peking University
- Tel Aviv University
- University of Ulsan
- Jiao Tong University
- Chungnam National University
- Sun Yat-Sen University
- Ospedale S. Bortolo
- Azienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele
- A.O. Bianchi-Melacrino-Morelli
- University of Texas at Houston
- University of Barcelona
- Soonchunhyang University
- University of Zaragoza
- +10 more
Organization Involved with Phase 3 Indications (72)
- Roche
- Avillion
- Hamad Medical Corporation
- Il-Yang Pharm. Co., Ltd.
- Teva
- Gamida Cell
- Center for International Blood and Marrow Transplant Research
- Central European Leukemia Study Group
- Medical Research Council
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Marrow Donor Program
- University of Jena
- University Hospital Freiburg
- University of Pittsburgh
- Case Western Reserve University
- University of London
- Harvard University
- Dartmouth University
- Temple University
- German CML Study Group
- University of Washington
- Gruppo Italiano Trapianto di Midollo Osseo
- Harbin Medical University
- Institut Bergonié
- Loyola University
- Medical College of Wisconsin
- Medical University Innsbruck
- New York Blood Center
- Newcastle University
- +42 more
Organization Involved with Phase 2 Indications (216)
- PPD
- S*BIO
- Incyte
- AbbVie
- ChemGenex Pharmaceuticals
- Eisai
- Takeda
- Celgene
- Cephalon
- Shire
- Amgen
- Astellas
- Schering-Plough
- Genzyme
- Sanofi
- AOP Orphan Pharmaceuticals AG
- Array BioPharma
- Ascentage Pharma Group Inc.
- Bayer
- Bio-Path Holdings, Inc.
- BioLineRx, Ltd.
- Cell Therapy Catapult
- Celldex Therapeutics
- Cellerant Therapeutics
- Fate Therapeutics
- Fusion Pharma LLC
- GWT-TUD GmbH
- Hengrui Therapeutics, Inc.
- Hikma
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- +186 more
Organization Involved with Phase 1 Indications (51)
- Daiichi Sankyo
- Millennium Pharmaceuticals
- Cato Research
- Immunomedics
- Exelixis
- MediGene
- Athersys, Inc
- Bellicum Pharmaceuticals
- CTI BioPharma
- Deciphera Pharmaceuticals LLC
- Erimos Pharmaceuticals
- Karyopharm Therapeutics Inc
- Kyowa Hakko Kirin
- Synta Pharmaceuticals Corp.
- Constant Pharmaceuticals
- Sunesis Pharmaceuticals
- Threshold Pharmaceuticals
- Chong Kun Dang Pharmaceutical
- CytRx
- AIDS Malignancy Consortium
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Duke University
- Nanjing Medical University
- New York University
- Tufts University
- University of Kansas
- University of Rochester
- University of Southern California
- Wayne State University
- Assiut University
- +21 more
Organization Involved with Other Experimental Indications (13)